Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2018 October;73(5) > Minerva Chirurgica 2018 October;73(5):488-96

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Chirurgica 2018 October;73(5):488-96

DOI: 10.23736/S0026-4733.18.07512-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Development of epidermal growth factor receptor targeted therapy in pancreatic cancer

Liu QING, Wang QING

Department of Endocrinology, China-Japan Union Hospital of Jilin University, Changchun, China


PDF


The epidermal growth factor receptor (EGFR) family is a series of important cancer therapeutic targets involved in cancer biology. These genes play an important role in tumor biological characteristics including angiogenesis, cell survival, invasion and glucose metabolism. In recent years, progress has been achieved on the cellular and molecular biological characteristics of EGFR and its role in cancer development based on the study of tumor specimens and experimental animal model. EGFR (HER1/ErbB) is overexpressed in over sixty percent of triple-negative breast cancers and occurs in pancreatic, bladder, lung and head-and-neck cancers. Up to now, EGFR inhibitors have been applied in various types of cancer, such as lung cancer, breast cancer, bladder cancer and head and neck cancers etc., in which the combination of EGFR inhibitors plus chemotherapeutic agents is now seen as the standard of cure for advanced/metastatic pancreatic cancer. For these reasons, EGFR inhibitors and their therapeutic effect for pancreatic cancer is becoming the focus in laboratory and clinical research. In this paper, research progress of the development of epidermal growth factor receptor targeted therapy in pancreatic cancer is introduced.


KEY WORDS: Receptor, epidermal growth factor - Molecular targeted therapy - Pancreatic neoplasms

top of page